The United Nations agency released for the first time report vaccine manufacturing process is currently under development, to guide further investment and research.
Antibiotic resistance occurs when bacteria, viruses, fungi, and parasites change over time and no longer respond to medications, making infections more difficult to treat and increasing the risk of disease spread, serious illness, and disease. dead.
Millions of people died
This “silent pandemic” is a growing public health concern. WHO speak.
Infections caused by resistant bacteria alone are associated with nearly five million deaths each year, and more than 1.2 million deaths are directly attributable to AMR.
The report identifies 61 vaccine candidates, some of which are in the late stages of development although most will not be available anytime soon.
“Preventing infection using vaccines reduces antibiotic use, one of the main drivers of AMR,” said Dr. Hanan Balkhy, WHO Assistant Director-General for Drug Resistance.
Fair Access
However, of the six bacterial pathogens that cause death from AMR, only one – the pneumococcal disease – has a vaccine.
“Fair and equitable access to life-saving vaccines, such as the pneumococcal vaccine, is needed to save lives and mitigate the rise of AMR,” she said.
WHO has also called for equitable and global access to vaccines that already exist, such as those against four priority bacterial pathogens including pneumococcal disease, tuberculosis and tuberculosis. weld.
Learning from the pandemic
“Disruptive approaches are needed to enrich the pipeline and accelerate vaccine development. Lessons from COVID-19 Dr Haileyesus Getahun, Director of the agency’s AMR Global Coordination Division, said: “Vaccine development and mRNA vaccines present unique opportunities to explore the development of vaccines against bacteria.” .
The report also examines some of the challenges facing vaccine innovation and development, including pathogens associated with hospital-acquired infections.
Issues include the difficulty of identifying the target population among all hospitalized patients, the cost and complexity of vaccine efficacy trials, and the lack of regulatory or political precedent. book for vaccines against infections.
“Vaccine development is expensive and scientifically challenging, often has a high failure rate, and for successful candidates, complex regulatory and manufacturing requirements require additional time. We must capitalize on the lessons of COVID vaccine development and accelerate the search for a vaccine to tackle AMR,” said Dr Kate O’Brien, Director of the WHO Immunization, Vaccines and Biologicals Division know.
